Citation

Sanders K, Lim S, Ortega S, Gimbel M, Mina L (2019) Exemestane-Induced Eosinophilic Colitis in a Patient with Grade 3 Ductal Carcinoma In-Situ: A Case Report and Review of the Literature. Int J Cancer Clin Res 6:104. doi.org/10.23937/2378-3419/1410104

Copyright

© 2019 Sanders K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CASE REPORT | OPEN ACCESSDOI: 10.23937/2378-3419/1410104

Exemestane-Induced Eosinophilic Colitis in a Patient with Grade 3 Ductal Carcinoma In-Situ: A Case Report and Review of the Literature

Kristyn Sanders1#, Shannon Lim1#, Sandra Ortega RN2#, Mark Gimbel3# and Lida Mina4#*

1Department of Pharmacy, Banner MD Anderson Cancer Center, USA

2Department of Case Management, Banner MD Anderson Cancer Center, USA

3Department of Surgical Oncology, Banner MD Anderson Cancer Center, USA

4Department of Breast Medical Oncology, Banner MD Anderson Cancer Center, USA

#Equal contribution: All authors contributed equally to the writing and publication of this manuscript

Abstract

Purpose

A case report of eosinophilic colitis associated with exemestane use is presented.

Summary

Approximately after three months of exemestane therapy for breast cancer risk reduction, a 60-year-old female with estrogen receptor positive, right breast ductal carcinoma in situ (DCIS) presented to the emergency room with severe abdominal pain, nausea, vomiting, and diarrhea. Imaging studies revealed severe colitis of the transverse colon. No other medications were started except for exemestane that would have contributed to the patient's symptoms. Outpatient workup included stool cultures, laboratory studies, and esophagogastroduodenoscopy and colonoscopy with biopsies. Results of the studies were significant for eosinophilic colitis and moderate to borderline severe colitis with increased eosinophilia. The patient was subsequently started on corticosteroids and discontinued exemestane. Her symptoms resolved in two weeks. Approximately two months later, the patient was started on tamoxifen for breast cancer prevention, which she tolerated well.

Conclusion

Exemestane was deemed the probable cause of the acute episode of eosinophilic colitis in this case. One other prior case with aromatase inhibitor-induced eosinophilic colitis has been reported with letrozole, however this is the first case report of eosinophilic colitis associated with exemestane.